Core Vct I Share Discussion Threads

[yawn3] 19/2/2018 10:49

GUN

Buyers continuing

[cpap man] 19/2/2018 09:53

UOG



WiltshireRam19 Feb '18 - 09:40 - 175 of 175

I firmly believe that this is one of those rare opportunities when you can get into a company right at the start of what will turn out to be a very rewarding and successful journey:

- a sound strategy (dont put all your eggs in one basket, have some 'bread and butter' and relatively safe projects in Europe that will ensure long term sustainability and then add in some potential huge but riskier upside projects in Latin America and Africa).

- a really experienced and pragmatic management team - a team further strengthened with today's announcement. They've been there before

- links to oil majors and super majors who are approaching UOG to partner

- an opportunity in Jamaica that is just extrordinary

- the likelihood of more good deals to come.

- any fundraising accompanied by good news resulting in positive share price reactions

- on the main market rather than the wild west that is AIM.

I've been stake building here for some months now and will continue to do so. I am super positive about this one.

Of course, the above are just my opinions and do your own research - I'd thoroughly recommend last week's investor call if you want to find out more

[cpap man] 19/2/2018 09:08

UOG



UOG now sitting at the highs for the day so far!

[cpap man] 19/2/2018 08:15

UOG



Commenting on the new appointment, Brian Larkin, Chief Executive Officer, said:



"We are delighted to welcome Graham to our Board and to see him assume the role of Chairman. We have, from the outset, stated a clear vision to build an oil and gas company that will successfully operate in exploration, development and production stages. Graham's addition to our Board will further strengthen our strategic and corporate experience and will help us in achieving this goal and in ultimately delivering superior shareholder returns.

[cpap man] 19/2/2018 07:53

UOG



Absolutely amazing news this morning from UOG and just to think that this is just the tip of the iceberg!

[cpap man] 19/2/2018 07:49

UOG



Amazing achievement by UOG to land such an experienced appointment!! This guy must see the huge potential here..!! Onwards and upwards....!!!

More ex tullow personnel excellent for the company

[cpap man] 19/2/2018 07:22

UOG



Monday 19 February, 2018
United Oil & Gas PLC
Board Appointment
RNS Number : 2050F
United Oil & Gas PLC
19 February 2018

[19] February 2018



United Oil & Gas Plc

Board Appointment



United Oil & Gas Plc ("UOG", "United" or the "Company"), the London Stock Exchange listed oil and gas exploration and development company, is pleased to announce that Mr. Graham Martin has joined the Board as a Non-Executive Chairman with immediate effect.



Mr. Martin is an experienced senior natural resources executive and brings a wealth of international expertise. He is currently a Non-Executive Director at Kenmare Resources plc, one of the leading global producers of titanium minerals and zircon listed in London and Dublin. He has also previously served as an Executive Director, General Counsel and Company Secretary at Tullow Oil plc. From 1997 until 2016, Mr. Martin was centrally involved in the growth of Tullow Oil plc into a FTSE100 business, and in the company's transformative M&A programme. Prior to Tullow Oil plc, Mr. Martin was a partner at the US energy law firm Vinson & Elkins LLP, having started his legal career in Scotland.



Commenting on the new appointment, Brian Larkin, Chief Executive Officer, said:



"We are delighted to welcome Graham to our Board and to see him assume the role of Chairman. We have, from the outset, stated a clear vision to build an oil and gas company that will successfully operate in exploration, development and production stages. Graham's addition to our Board will further strengthen our strategic and corporate experience and will help us in achieving this goal and in ultimately delivering superior shareholder returns.

[hottingup] 18/2/2018 12:39

This promising small-cap stock could be a millionaire maker in 2018
Paul Summers
Tue. 26/12/2017



The suggestion that a single stock could lead some investors to become millionaires next year may sound fanciful but I think this is quite possible if events work out for small-cap drug discovery and development firm ImmuPharma (LSE: IMM). Let me explain.

Blockbuster potential

Over the last three months, shares in the AIM-listed company have climbed more than 200% in value as anticipation grows over the outcome of a Phase III clinical trial for Lupuzor — its 100%-owned potential treatment for Lupus.

Approximately five million people are believed to suffer from the chronic and potentially life-threatening autoimmune disease that can be a notoriously difficult to treat. In the last 50 years, only one therapy — GlaxoSmithKline‘s Benlysta — has been approved for use, despite its questionable efficacy and serious side-effects. In 2015, the drug achieved sales of over $400m. By 2020, this figure is expected to rise to $1bn.

Positively, data from Lupozor’s Phase IIb trial indicated that ImmuPharma’s treatment — which modulates rather than blocks the immune system — was both effective and safe. Moreover, the effectiveness of Lupuzor increased even after the three-month trial’s conclusion. Investors will be hoping that the 52-week, randomised and double-blinded study currently in progress (involving patients in the US, Europe and Mauritius) yields similar results.

In its most recent update on 21 December, the company revealed that all 200 participants had now received the full 12-month dosage and that the “robust safety record” shown in earlier trials continues to be seen. According to Chairman Tim McCarthy, the company looks forward “with continued confidence” to reporting on top-line results in Q1 of next year.

In the event of a positive outcome, ImmuPharma will then seek to exploit its Fast Track designation and push for approval from the Food and Drug Administration (FDA). Once received, the company would then be free to seek out a global licensing deal for taking Lupuzor to market or — perhaps more likely — consider takeover bids by deep-pocketed pharmaceutical giants at a price befitting its blockbuster potential. Given the suggestion that it could be used in the treatment of other diseases, the price could easily be in the billions of pounds. Right now, ImmuPharma’s market cap is a little over £200m.


Northland Capital, 18/1/2018

"Should Lupuzor successfully meet the trial endpoints, we estimate that ImmuPharma’s shares would significantly rerate to the upside. Finally, it is encouraging to see demand from patients for a follow-up study."

[the stigologist] 18/2/2018 07:40

PYC

3 big pharma deals in 3 months
In talks with 50 potential clients
SUBSTANTIAL NON-DILUTIVE FUNDING
A stock which has recently demonstrated ability to go from 1p to 32p in space of 48 hours
£4m Market Cap is crazy when it's nearest comp was taken out for $850m a few months back

[yawn3] 16/2/2018 16:29

GUN

Tick Tick

[money maker1] 16/2/2018 13:50

ImmuPharma (IMM) about to rocket.

[cudmore] 16/2/2018 10:36

VAL news on its way. share price will quadruple when the news leaks.

[yawn3] 16/2/2018 10:22

YOLO

Drifting further. Boom as they say.

[hottingup] 16/2/2018 08:23

This promising small-cap stock could be a millionaire maker in 2018
Paul Summers
Tue. 26/12/2017



The suggestion that a single stock could lead some investors to become millionaires next year may sound fanciful but I think this is quite possible if events work out for small-cap drug discovery and development firm ImmuPharma (LSE: IMM). Let me explain.

Blockbuster potential

Over the last three months, shares in the AIM-listed company have climbed more than 200% in value as anticipation grows over the outcome of a Phase III clinical trial for Lupuzor — its 100%-owned potential treatment for Lupus.

Approximately five million people are believed to suffer from the chronic and potentially life-threatening autoimmune disease that can be a notoriously difficult to treat. In the last 50 years, only one therapy — GlaxoSmithKline‘s Benlysta — has been approved for use, despite its questionable efficacy and serious side-effects. In 2015, the drug achieved sales of over $400m. By 2020, this figure is expected to rise to $1bn.

Positively, data from Lupozor’s Phase IIb trial indicated that ImmuPharma’s treatment — which modulates rather than blocks the immune system — was both effective and safe. Moreover, the effectiveness of Lupuzor increased even after the three-month trial’s conclusion. Investors will be hoping that the 52-week, randomised and double-blinded study currently in progress (involving patients in the US, Europe and Mauritius) yields similar results.

In its most recent update on 21 December, the company revealed that all 200 participants had now received the full 12-month dosage and that the “robust safety record” shown in earlier trials continues to be seen. According to Chairman Tim McCarthy, the company looks forward “with continued confidence” to reporting on top-line results in Q1 of next year.

In the event of a positive outcome, ImmuPharma will then seek to exploit its Fast Track designation and push for approval from the Food and Drug Administration (FDA). Once received, the company would then be free to seek out a global licensing deal for taking Lupuzor to market or — perhaps more likely — consider takeover bids by deep-pocketed pharmaceutical giants at a price befitting its blockbuster potential. Given the suggestion that it could be used in the treatment of other diseases, the price could easily be in the billions of pounds. Right now, ImmuPharma’s market cap is a little over £200m.


Small caps poised for big news in 2018:
We look at 19 stocks primed to deliver major events in their career
21/12/2017



"Drug developer ImmuPharma (IMM) is expecting Phase III results in the first quarter of 2018 for lupus treatment Lupuzor. Analysts speculate the drug could hit multi-billion dollar annual sales if the tests are successful and the drug gets approved by the regulators."

[marmar80] 16/2/2018 07:55

Read about bioplastics lads. The future is now, but very quiet about it. Game over for plastic in food packaging, coffee cups etc. Go biome.

[lithological heterogeneities] 16/2/2018 07:45

BPC

Extremely important high risk comment.

BPC license ENDS in April (6 weeks time) and if not renewed could go bust. (but have renewed it often with the Bahamas government over the past few years).

But read the above and decide if the risk is worth it.

[lithological heterogeneities] 16/2/2018 07:43

BPC

WATCH BPC OVER THE COMING WEEKS.

VERY ADVANCED FARM-IN TALKS WITH MULTIPLE PARTIES.

GOVERNMENT JUST ANNOUNCED YESTERDAY THE START OF A $5.5B OIL INFRASTUCTURE PROGRAMME.

WILL BE ANNOUNCED TIS MONDAY FOLLOWED BY TWO MORE HOA'S THE FOLLOWING 2 MONDAYS.

"additional announcements to be made regarding Grand Bahama’s revitalization over the next few weeks.” as well !

[lithological heterogeneities] 16/2/2018 07:40

BPC in very adanced farm-in talks to begin drilling their 28 billion barel upside licenses in 2018.

5 NEW parties visited the Data room at end of 2017. This isn in addition to the parties that have ALREADY visited the Data Room.


02 OCT 2017
Oil Explorer's Boost For 'Faster' Farm-In Partner Conclusion


"This has included executing several new Non-Disclosure Agreements with parties interested in reviewing the investment opportunity, five new parties undertaking or scheduling due diligence visits to assess the company's technical database, and commencement of dialogue with various industry intermediaries to broaden the scope and reach of the company's efforts."

At the same time, discussions have continued with those parties that had already undertaken substantial technical and commercial due diligence our hope being to progress one or more party to the next stage of the process (non-binding term sheets) in the next couple of months."

[lithological heterogeneities] 16/2/2018 07:36

UPSIDE = 28 BILLION BARRELS OF OIL !
MKT CAP = £20.4M !!

BPC - 16 FEB 2018
Shares in Issue...1,510,479,096
Share price ...1.35p
Mkt Cap...£20.4m

11 JAN 2018
Oil Explorer's Success Prospects 'Four Times' Better Than Average


Independent experts Moyes & Co says economically recoverable oil between a mean of 8.3 billion barrels to "an upside" of 28 billion barrels (BPC Mkt Cap just £20.4m!)

Independent experts Moyes & Co who confirmed its chances of success are at least four times' higher than the industry average.

"probability of success" for each of the seabed oil sources it is targeting as between 25 per cent to 35 per cent

this far exceeded the oil industry's typical 5-10 per cent average


RNS - MOYES & CO BPC TECHNICAL AUDIT (20 Dec 17)

[lithological heterogeneities] 16/2/2018 07:35

BAHAMAS PETROLEUM (BPC) !

15 FEB 18
Govt to sign HOA for $5.5 billion oil facility in GB


The first of three heads of agreement (HOA) that will facilitate the development of a $5.5 billion oil refinery and storage facility complex on Grand Bahama will be signed on Monday between Oban Energies and the government of The Bahamas.

“We look forward to the additional announcements to be made regarding Grand Bahama’s revitalization over the next few weeks.”

Following Monday’s HOA signing, two others will be signed the two following Mondays.

[lithological heterogeneities] 16/2/2018 07:32

BAHAMAS PETROLEUM (BPC) !

UPSIDE = 18 BILLION BARRELS OF OIL
MKT CAP = £20.4M

Massive news announced by Bahamas Government yesterday !
$5.5 billion oil infrasture deal to be announced on Monday followed by two more Oil related Heads Of Agreements to be signed on the following 2 Mondays !
last week the Bahamas government confirmed they were in talks regarding "house keeping" with BPC.

[patientcapital] 15/2/2018 07:58

MXCP breaking out. JV with LIBERTY GLOBAL.

[patientcapital] 15/2/2018 07:58

MXCP breaking out. JV with LIBERTY GLOBAL.

[daniel levi bmd] 14/2/2018 10:51

Eyes on.

FYI

On-Line Blockchain PLC News on the way? The Blockchain Rollercoaster. Fasten Your Belts..


Dan
x